IFNγ Signaling in Natural and Therapy-Induced Antitumor Responses
- PMID: 34785585
- DOI: 10.1158/1078-0432.CCR-21-3226
IFNγ Signaling in Natural and Therapy-Induced Antitumor Responses
Abstract
IFNγ is a cytokine produced by a restricted number of immune cells that acts on every nucleated cell type. Consistent with this remarkably wide spectrum of targets, the effects of IFNγ are highly pleiotropic. On cells of the immune system, IFNγ signaling has generally a pro-inflammatory effect, coordinating the innate and adaptive responses. On nonimmune cells, IFNγ tends to exert the opposite effect; it inhibits cell proliferation, induces cell death, and, in addition, promotes their recognition by the immune system. These effects on the immune and nonimmune compartments play a crucial role during the immunoediting of tumors and, as shown by recent reports, also determine the efficacy of certain immunotherapies. Different therapeutic interventions to target IFNγ signaling are currently under way, and the emerging picture indicates that rewiring IFNγ signaling, disrupted in some cancer cells, may be an efficacious antitumor therapeutic strategy.
©2021 American Association for Cancer Research.
Similar articles
-
Dual Faces of IFNγ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity.Clin Cancer Res. 2016 May 15;22(10):2329-34. doi: 10.1158/1078-0432.CCR-16-0224. Epub 2016 Mar 25. Clin Cancer Res. 2016. PMID: 27016309
-
Selective targeting of interferon γ to stromal fibroblasts and pericytes as a novel therapeutic approach to inhibit angiogenesis and tumor growth.Mol Cancer Ther. 2012 Nov;11(11):2419-28. doi: 10.1158/1535-7163.MCT-11-0758. Epub 2012 Aug 29. Mol Cancer Ther. 2012. PMID: 22933708
-
IFNγ influences type I interferon response and susceptibility to Theiler's virus-induced demyelinating disease.Viral Immunol. 2013 Aug;26(4):223-38. doi: 10.1089/vim.2013.0004. Epub 2013 Jul 5. Viral Immunol. 2013. PMID: 23829778 Free PMC article.
-
Interferon-γ: teammate or opponent in the tumour microenvironment?Nat Rev Immunol. 2022 Mar;22(3):158-172. doi: 10.1038/s41577-021-00566-3. Epub 2021 Jun 21. Nat Rev Immunol. 2022. PMID: 34155388 Free PMC article. Review.
-
STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNγ, TLR4 and IL-6 in vascular disease.Cytokine Growth Factor Rev. 2011 Aug;22(4):211-9. doi: 10.1016/j.cytogfr.2011.06.003. Epub 2011 Jul 12. Cytokine Growth Factor Rev. 2011. PMID: 21752694 Review.
Cited by
-
Macrophage-Centric Immunometabolic Crosstalk in Alopecia Areata Pathogenesis: Mechanisms and Therapeutic Implications.Clin Rev Allergy Immunol. 2025 May 22;68(1):50. doi: 10.1007/s12016-025-09060-3. Clin Rev Allergy Immunol. 2025. PMID: 40405030 Review.
-
Arrest and Attack: Microtubule-Targeting Agents and Oncolytic Viruses Employ Complementary Mechanisms to Enhance Anti-Tumor Therapy Efficacy.Genes (Basel). 2024 Sep 11;15(9):1193. doi: 10.3390/genes15091193. Genes (Basel). 2024. PMID: 39336785 Free PMC article. Review.
-
The Emerging Role of IL-9 in the Anticancer Effects of Anti-PD-1 Therapy.Biomolecules. 2023 Apr 12;13(4):670. doi: 10.3390/biom13040670. Biomolecules. 2023. PMID: 37189417 Free PMC article. Review.
-
Anti-CSF-1R therapy with combined immuno- chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched Triple Negative Breast Cancers.bioRxiv [Preprint]. 2025 May 6:2025.04.30.651522. doi: 10.1101/2025.04.30.651522. bioRxiv. 2025. PMID: 40568104 Free PMC article. Preprint.
-
Epstein-Barr virus DNA seropositivity links distinct tumoral heterogeneity and immune landscape in nasopharyngeal carcinoma.Front Immunol. 2023 Feb 13;14:1124066. doi: 10.3389/fimmu.2023.1124066. eCollection 2023. Front Immunol. 2023. PMID: 36860875 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical